Antibody-drug conjugate

Where the papers sit

14 papers from the last 6 months study antibody-drug conjugate directly · updated from PubMed 11 Oct 2026

• Targeted ADCs in Advanced Cancer

  Targeted ADCs are expanding beyond pretreated triple-negative breast cancer into uterine, prostate and pancreatic cancers. Sacituzumab govitecan and other TROP2-directed agents anchor clinical work, with progression-free survival and real-world treatment outcomes recurring endpoints. Combination therapy and new targets such as CDCP1 are being explored alongside monotherapy. The field is moving toward precision delivery, but efficacy across tumor types and treatment settings remains uneven.

  7 papers · 50%

• HER2-Targeted Breast Cancer Therapy

  HER2-directed treatment is moving toward biomarker-guided ADC selection and rational combination strategies. Spatial proteogenomics and mass cytometry are being used to identify resistance and sensitization states in HER2-positive disease. Tucidinostat, H3K27ac-linked regulation and HER2 inhibitors point to epigenetic and signaling changes that may improve response. Conjugation platforms and EGFR-targeting broaden the delivery technology, but their clinical role remains less defined.

  4 papers · 28.6%

• ADC Clinical Development and Delivery

  ADC development is focusing on managing unexpected toxicity while improving how these drugs reach patients. Promiscuous payload activity, linker stability, exposure and cytotoxicity are recurring safety concerns during clinical development. Subcutaneous delivery is being engineered as an alternative to intravenous administration, with convenience and pharmacokinetics still to establish. Clinical-trial design and risk assessment remain central to translating these improvements into practice.

  3 papers · 21.4%